Literature DB >> 18376576

[From waiting to pro-active health care. The main road to build the second pillar of health system].

G Maciocco1.   

Abstract

The waiting paradigm is typical of acute diseases: one waits for an event upon which to act, a problem to solve. Waiting is the classical health care paradigm of the bio-medical model, upon which has always been based the university training. It is not astonishing that it also became the dominant paradigm in the territorial and primary care. Pro-active health care is the best fitted to manage primary care in general and chronic diseases in particular (including mental illnesses and drug addictions), where the support is mainly "extensive" and characterized by a long term case-management. Here, the added value of the health care processes is in the ability to preserve the continuity of care and in the quality of the relationship, the trust, between the system and its clients, the service providers and the service users. An overview of international experiences.

Entities:  

Mesh:

Year:  2007        PMID: 18376576

Source DB:  PubMed          Journal:  Ann Ig        ISSN: 1120-9135


  2 in total

1.  Systematic age-related differences in chronic disease management in a population-based cohort study: a new paradigm of primary care is required.

Authors:  Alessandra Buja; Gianfranco Damiani; Rosa Gini; Modesta Visca; Bruno Federico; Daniele Donato; Paolo Francesconi; Alessandro Marini; Andrea Donatini; Salvatore Brugaletta; Vincenzo Baldo; Maria Donata Bellentani
Journal:  PLoS One       Date:  2014-03-14       Impact factor: 3.240

2.  Prevalence of chronic diseases by immigrant status and disparities in chronic disease management in immigrants: a population-based cohort study, Valore Project.

Authors:  Alessandra Buja; Rosa Gini; Modesta Visca; Gianfranco Damiani; Bruno Federico; Paolo Francesconi; Daniele Donato; Alessandro Marini; Andrea Donatini; Salvatore Brugaletta; Vincenzo Baldo; Mariadonata Bellentani
Journal:  BMC Public Health       Date:  2013-05-24       Impact factor: 3.295

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.